Economic analysis of rivaroxaban for the treatment and long-term prevention of venous thromboembolism in Portugal;Estudo de avaliação económica de rivaroxabano para tratamento e prevenção a longo-prazo de tromboembolismo em portugal

Acta Medica Portuguesa

Volumn 27, Issue 5, 2014, Pages 615-624

  Santos, Isabel Fonseca ^a   Pereira, Sónia ^a   McLeod, Euan ^b   Guillermin, Anne Laure ^b   Chatzitheofilou, Ismini ^b  

^a Bayer Portugal SA   (Portugal)

^b IQVIA   (United States)

Author keywords

Cost Benefit Analysis; Pulmonary Embolism; Rivaroxaban; Venous Thromboembolism; Venous Thrombosis

Indexed keywords

ENOXAPARIN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; ECONOMIC ASPECT; HUMAN; LONG TERM CARE; LUNG EMBOLISM; MORTALITY; PORTUGUESE (CITIZEN); QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; COMPARATIVE STUDY; COST; ECONOMIC MODEL; ECONOMICS; PORTUGAL; TIME FACTOR;

ANTICOAGULANTS; COSTS AND COST ANALYSIS; ENOXAPARIN; FACTOR XA INHIBITORS; HUMANS; MODELS, ECONOMIC; PORTUGAL; QUALITY-ADJUSTED LIFE YEARS; RIVAROXABAN; TIME FACTORS; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 84908464283     PISSN: 0870399X     EISSN: 16460758     Source Type: Journal    
DOI: 10.20344/amp.5257     Document Type: Article

References (46)

1. Reis A, Rocha N, Santos M, Gonçalves F, Soares A, Marques I, et al. Normas para a prevenção, diagnóstico e tratamento do tromboembolismo venoso no doente médico. Rev Port Med Interna. 2010;17:37-58
2. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, et al. VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98:756-64.
3. Pengo V, Lensing A., Prins MH, Marchiori A, Davidson BL, Tiozzo F, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004:27:2257-64.
4. Lang IM, Klepetko W. Update on chronic thromboembolic pulmonary hypertension, a frequently undiagnosed condition. Rev Esp Cardiol. 2009;62:120-5.
5. Becattini C, Agnelli G, Pesavento R, Silingardi M, Poggio R, Talliani MR, et al. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest. 2006;130:172-5.
6. Cohen AT, Dobromosrski M. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism. Thromb Haemost. 2012;107:1035-43.
7. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th edition. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141: e419S-94.
8. Snow V, Qaseem A, Barry P, Hornbake ER, Rodnick JE, Tobolic T, et al. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med, 2007;146:204-10.
9. Nicolaides A, Hull RD, Fareed J. Prevention and treatment of venous thromboembolism: international consensus statement (guidelines according to scientific evidence). Clin Appl Thromb Hemost. 2013;19:116-8.
10. Excellence, National Institute for Health and Clinical. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. NICE Clinical Guideline 144.2012; [consultado 2011 Mai 27]. Disponível em: http://www.nice. org.uk/nicemedia/live/13767/59720/59720.pdf.
11. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Orientações para o diagnóstico e tratamento da hipertensão pulmonar. Rev Port Cardiol, 2012;31:11-75.
12. Buller HR, Sohne M, Middeldorp S. Treatment of venous thromboembolism. J Thromb Haemost. 2005;3:1554-60.
13. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th ed. Chest. 2008;133:454S-545.
14. Bounameaux H, Perrier AA. Duration of anticoagulation therapy for venous thromboembolism. Hematology Am Soc Hematol Educ Program. 2008;252-8.
15. Warkentin TE, Greinacher A, Koster A, Lincoff AM, Physicians, American College of Chest. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. 8th ed. Chest. 2008;133:340S-80.
16. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th ed. Chest. 2008;133:160S-98.
17. Investigators, The EINSTEIN. Oral rivaroxaban for symptomatic venous thromboembolism. N Eng J Med. 2010;363:2499-510.
18. Investigators, The EINSTEIN-PE. Oral rivaroxaban for symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287-97.
19. Quarterly of the European Observatory on Health Systems and Policies. EuroHealth 18. 1. Health systems and the financial crisis. [consultado 2013 Nov 26]. Disponível em: http://www.euro.who.int/__data/assets/pdf_file/0005/162959/Eurohealth_Vol-18_No-1_web.pdf.
20. Aujesky D, Smith KJ, Cornuz J, Roberts MS. Cost-effectiveness of lowmolecular- weight heparin for treatment of pulmonary embolism. Chest. 2005;128:1601–10.
21. Aujesky D, Smith KJ, Roberts MS. Oral anticoagulation strategies after a first idiopathic venous thromboembolic event. Am J Med. 2005;118:625–35.
22. Gomez-Outes A, Berto P, Prandoni P. Cost-effectiveness of bemiparin in the prevention and treatment of venous thromboembolism. Expert Rev Pharmacoecon Outcomes Res. 2006;6:249–59.
23. Marchetti M, Pistorio A, Barone M, Serafini S, Barosi G, et al. Lowmolecular- weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. Am J Med. 2001;111:130–9.
24. Caro JJ, Getsios D, Caro I, O’Brien JA. Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis. Pharmacoeconomics. 2002;20:593-602.
25. Silva EA, Pinto C, Sampaio C, Pereira JA, Drummond N, Trindade R. Orientações Metodológicas para Estudos de Avaliação Económica de Medicamentos. Lisboa: Ministério da Saúde/INFARMED; 1998.
26. European Medicines Agency (EMA)/Committee for Medicinal Products for Human Use (CHMP). Xarelto Assessment Report. Procedure No.: EMEA/H/C/000944/X/0010. 2011. EMA/CHMP/301607/2011.
27. Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92:199-205.
28. Prandoni P, Villalta S, Bagatella P, Rossi L, Marchiori A, Piccioli A, et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997;82:423-8.
29. Miniati M, Monti S, Bottai M, Scoscia E, Bauleo C, Tonelli L, et al. Survival and restoration of pulmonary perfusion in a long-term follow-up of patients after acute pulmonary embolism. Medicine. 2006;85:253-62.
30. Instituto Nacional de Estatística. Tábua completa de mortalidade para Portugal 2008-2010; [consultado 2011 Mai 27]. Disponível em: http://www.ine.pt/xportal/xmain?xpid=INE&xpgid=ine_destaques&DESTAQUESdest_boui=107454674&DESTAQUESmodo=2&xlang=pt.
31. Linkins L, Oædonnell M, Julian JA, Kearon C. Intracranial and fatal bleeding according to indication for long term oral anticoagulant therapy. J Thromb Haemost. 2010;8:2201-7.
32. Condliffe R, Kiely DG, Gibbs JSR, Corris PA, Peacock AJ, Jenkins DP, et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2008;177:1122-27.
33. Drummond MJ, O’Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford Medical Publications; 1997.
34. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ. 1998;316:736–41.
35. Locadia M, Bossuyt PM, Stalmeier PF, Sprangers MA, van Dongen CJ, Middeldorp S, et al. Treatment of venous thromboembolism with vitamin K antagonists: patients’ health state valuations and treatment preferences. Thromb Haemost. 2004;92:1336–41.
36. Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: potential applications in the treatment of deep venous thrombosis. J Am Med Inform Assoc. 1997;4:49-56.
37. Rivero-Arias O, Ouellet M, Gray A, Wolstenholme J, Rothwell PM, Luengo-Fernandez R. Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Med Decis Making. 2010;30:341-54.
38. Meads DM, McKenna SP, Doughty N, Das C, Gin-Sing W, Langley J, et al. The responsiveness and validity of the CAMPHOR Utility Index. Eur Respir J. 2008;32:1513-9.
39. Ministério da Saúde. Portaria n.º 132/2009, de 30 de Janeiro. Diário da República. 2009. I Série, N.º 21.
40. Portaria n.º 220/2011, de 11 de Junho. Diário da República, 2011. I Série, N.º 106.
41. Administração Central dos Serviços de Saúde. Contabilidade Analítica dos Hospitais do SNS. 2006; [Consultado 2013 Nov 26]. Disponível em: http://www.acss.min-saude.pt/Portals/0/DownloadsPublicacoes/SNS/Info_gestao/Contab_Analitica_2006_Hospitais_SNS.pdf.
42. Macedo A, Carrasco J, Andrade S, Moital S. Estudo de avaliação do custo incremental da auto-monitorização do INR versus controlo laboratorial ou monitorização no centro de saúde, em Portugal. Acta Med Port. 2010;23:203-12.
43. Kim SY, Goldie SJ, Salomon JA. Exploring model uncertainty in economic evaluation of health interventions: the example of rotavirus vaccination in Vietnam. Med Decis Making. 2010;30:E1–28.
44. Van Bellen B, Prins M, Bamber L, Wang M, Lensing A. Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the EINSTEIN trial program. Atlanta, GA, USA. Am Soc Hematol 54th Annual Meeting and Exposition. December 8-11, 2012.
45. White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107:I4-8.
46. Heit J, Cohen A, Anderson FJ. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood. 2005;106:267A.